1-2 of 2
Michael Constantine
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Omar Nadeem, Sophie Magidson, Robert A. Redd, Jacob P. Laubach, Clifton C. Mo, Elizabeth K. O'Donnell, Adam S. Sperling, Monique A. Hartley-Brown, Shonali Midha, Yuxin Liu, Frances Arters, Marjorie Marto, Christine Davie, Caroline Ricciardi, Dechen Choden, Ashlee Strutevant, Jillian Alberti, Amy Goguen, Michael Constantine, Pedro Sanz-Altamira, Lorenzo Trippa, Nikhil C. Munshi, Kenneth C. Anderson, Paul G. Richardson, Irene Ghobrial
Journal: Blood
Blood (2024) 144 (Supplement 1): 3360.
https://doi.org/10.1182/blood-2024-202653
Published: 2024
Journal Articles

Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Kenneth H. Shain, MD, Jacob Laubach, MD, Patrick Henrick, James Vredenburg, MD, Pamela Crilley, MD, Michael Constantine, MD, Caroline Block, MD, Frank G. Basile, MD, Joseph Cappuccio, Abdel Kareem Azab, BPharm, PhD, Emily Lai, Aaron Caola, Ranjit Banwait, Alexandra Savell, Nikhil C. Munshi, MD, Claudia E. Paba-Prada, MD, Robert L. Schlossman, MD, Stacey Chuma, BSN, Kimberly Noonan, NP, Kenneth C. Anderson, MD, Paul G. Richardson, MD
Journal: Blood
Blood (2015) 126 (23): 4256.
https://doi.org/10.1182/blood.V126.23.4256.4256
Published: 2015